From left: Myosana CEO Matthew Lumley, with co-founders Stanley Froehner and Nick Whitehead. (Myosana and UW Photos) The news: Myosana Therapeutics, a Seattle startup developing gene therapy ...

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a publicly traded biotech company developing new small molecule therapeutic approaches to ...

- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy ...

The contribution of selected physical development and muscular strength measures to general motor performance capacity was investigated in 55 seven to twelve year old boys. The physical development ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing orally bioavailable, small molecule therapies for musculoskeletal diseases, today ...

Dystroglycan, a muscle cell receptor whose dysfunction causes muscular dystrophy, actually has a critical role in brain development, researchers have discovered. Researchers at Stony Brook University ...